Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Grifols S.A. (GRFS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,146,033
  • Shares Outstanding, K 687,554
  • Annual Sales, $ 5,299 M
  • Annual Income, $ 704,630 K
  • 60-Month Beta 1.06
  • Price/Sales 2.50
  • Price/Cash Flow 13.62
  • Price/Book 2.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 0.31
  • Number of Estimates 3
  • High Estimate 0.32
  • Low Estimate 0.31
  • Prior Year 0.28
  • Growth Rate Est. (year over year) +10.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.92 +0.26%
on 03/21/19
20.13 -5.74%
on 03/04/19
unch (-0.03%)
since 02/21/19
3-Month
17.42 +8.93%
on 12/24/18
20.13 -5.74%
on 03/04/19
+1.18 (+6.60%)
since 12/21/18
52-Week
17.42 +8.93%
on 12/24/18
24.97 -24.01%
on 06/13/18
-1.97 (-9.38%)
since 03/21/18

Most Recent Stories

More News
Grifols PharmacyKeeper Receives KLAS Category Leader Award for Third Consecutive Year

Grifols has earned the honor of 2019 Category Leader in IV Workflow Management in the 2019 Best in KLAS: Software & Services report for its PharmacyKeeper Verification product.

GRFS : 19.02 (-0.52%)
GRF : 7.50 (+0.13%)
Grifols Receives FDA Approval for Procleix Babesia Assay for Donor Screening on Procleix Panther System

Grifols, a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, announced today that the U.S. Food and Drug Administration (FDA) approved...

GRFS : 19.02 (-0.52%)
GRF : 7.50 (+0.13%)
Grifols receives FDA approval of Erytra Eflexis®, the latest advancement in scalable blood typing solutions

- Erytra Eflexis is a fully automated, benchtop analyzer that performs pretransfusion compatibility testing

GRFS : 19.02 (-0.52%)
GRF : 7.50 (+0.13%)
Grifols Expands its Blood Typing Solutions Portfolio in the United States with Antisera Reagents

Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, today announced the expansion...

GRFS : 19.02 (-0.52%)
GRF : 7.50 (+0.13%)
Report: Exploring Fundamental Drivers Behind Itau Unibanco Holding S.A, Weibo, Redhill Biopharma, Shenandoah Telecommunications, Grifols, S.A, and Orthofix International N.V -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Itau Unibanco Holding S.A....

RDHL : 8.97 (+0.90%)
OFIX : 56.42 (+0.89%)
SHEN : 46.13 (+2.22%)
GRFS : 19.02 (-0.52%)
ITUB : 8.98 (-4.26%)
WB : 60.47 (-0.89%)
Grifols 2017 Annual Report on Form 20-F filed with the SEC on April 6, 2018

Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) announced that it has filed its 2017 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC") on April...

GRFS : 19.02 (-0.52%)
GRF : 7.50 (+0.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade GRFS with:

Business Summary

Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience...

See More

Key Turning Points

2nd Resistance Point 19.49
1st Resistance Point 19.30
Last Price 19.02
1st Support Level 18.97
2nd Support Level 18.83

See More

52-Week High 24.97
Fibonacci 61.8% 22.09
Fibonacci 50% 21.19
Fibonacci 38.2% 20.30
Last Price 19.02
52-Week Low 17.42

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar